Gram Peptides
Has Gram Peptides received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026 concerning products containing retatrutide and tirzepatide.
Letter facts
- Letter date
- March 31, 2026 (2026-03-31)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Online / Internet Pharmacy
- Products named
- Retatrutide (marketed as GLP-1-R peptide)Tirzepatide (marketed as GLP-2 peptide)Bacteriostatic Water for Injection
- Violation categories
- Unapproved new drug
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Factual Violation Summary
FDA says the website offered Retatrutide, Tirzepatide, and Bacteriostatic Water for Injection with labeling showing intended human drug use; no approved applications exist, so products are unapproved new drugs introduced into interstate commerce.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Unapproved new drug (FD&C Act section 505(a))
- Introduction/delivery into interstate commerce (sections 301(d) and 505(a))
- Drug intended for human use despite Research Use Only labeling
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- Royal Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.